Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
JNCCN, Volume/Issue: Volume 21: Issue 1
Online Publication Date: Jan 2023
DOI: https://doi.org/10.6004/jnccn.2022.7070Authors: Dirk Mehrens, MD, Kristina K.M. Kramer, BA, Lena M. Unterrainer, MD, MHBA, Leonie Beyer, MD, Peter Bartenstein, MD, Matthias F. Froelich, MD, MHBA, Fabian Tollens, MD, MSc, Jens Ricke, MD, Johannes Rübenthaler, MD, MHBA, Nina-Sophie Schmidt-Hegemann, MD, Annika Herlemann, MD, Marcus Unterrainer, MD, PhD, MHBA, and Wolfgang G. Kunz
This first economic analysis of 117Lu-PSMA-617 RLT shows notable long-term clinical benefits as measured in QALYs and indicates the cost-effectiveness of this new treatment option in certain scenarios compared with the SoC as used in the VISION trial. This analysis may guide the planning of infrastructure and resources for future implementation into clinical practice.